Comparative Pharmacology
Head-to-head clinical analysis: RAUSERPIN versus RAUWOLFIA SERPENTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUSERPIN versus RAUWOLFIA SERPENTINA.
RAUSERPIN vs RAUWOLFIA SERPENTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (15-20%)
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Category C
Category C
Antihypertensive
Antihypertensive